Niagen Bioscience (NAGE) Cash from Operations Growth (3y) (2016 - 2026)
Niagen Bioscience (NAGE) Cash from Operations Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,933.35 Bn | 1,933.29 Bn | - | - |
| 3 | Akari Therapeutics | 1,063.56 Bn | 1,063.56 Bn | - | - |
| 4 | BeOne Medicines | 468.54 Bn | 463.75 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 123.45 Bn | 116.20 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 63.57 Bn | 63.57 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.75 Bn | 34.74 Bn | 959.66 Mn | 34.32% |
| 10 | Niagen Bioscience | 257.73 Mn | 191.18 Mn | 19.98 Mn | -34.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.40% |
| Dec 31, 2025 | 60.65% |
| Sep 30, 2025 | 44.05% |
| Jun 30, 2025 | 32.34% |
| Mar 31, 2025 | 45.73% |
| Dec 31, 2024 | 55.17% |
| Sep 30, 2024 | 37.34% |
| Jun 30, 2024 | 67.78% |
| Mar 31, 2024 | 27.13% |
| Dec 31, 2023 | 208.99% |
| Sep 30, 2023 | 28.12% |
| Jun 30, 2023 | 60.16% |
| Mar 31, 2023 | 36.35% |
| Dec 31, 2022 | 18.68% |
| Sep 30, 2022 | 21.60% |
| Jun 30, 2022 | 24.83% |
| Mar 31, 2022 | -33.17% |
| Dec 31, 2021 | 1.26% |
| Sep 30, 2021 | -4.18% |
| Jun 30, 2021 | -6.43% |